Home » Topics » Regulatory » EMA

EMA
RSS

Intercell obtains positive CHMP opinion for pediatric use of its JE vaccine

Dec. 20, 2012

Roche's Perjeta receives CHMP recommendation for approval

Dec. 18, 2012

Alexza's MAA for Adasuve receives positive opinion from EMA advisory committee

Dec. 18, 2012

EMA committee recommends approval of Selincro for alcohol dependence

Dec. 17, 2012

Vanda's Fanaptum receives negative opinion from EMA

Dec. 17, 2012

EMA committee adopts negative opinion on MAA for Kynamro in HoFH

Dec. 17, 2012

The EMA validates PTC Therapeutics' MAA for ataluren

Dec. 10, 2012

FDA approves Cometriq, EMA accepts MAA

Nov. 30, 2012

EMA recommends granting orphan status to Aspireo's somatoprim

Nov. 26, 2012

EMA to begin formal review of macitentan MAA

Nov. 22, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...